Pilot: Impact of High-Dose, Single Fraction Radiation on Immunogenicity of Sipuleucel-T in Metastatic Castration Recurrent Prostate Cancer Patients
Status: Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 22 Oct 2019 Planned End Date changed from 6 Oct 2019 to 6 Oct 2020.
- 19 Sep 2019 Planned End Date changed from 6 Aug 2019 to 6 Oct 2019.
- 04 Jun 2019 Results (n=15) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.